Zollinger-Ellison Syndrome

MNC公司有很多新药项目需求，欢迎联系药时代BD团队（BD@drugtimes.cn）！近日，国家药监局发布的信息显示，海南三叶制药厂的奥美拉唑肠溶胶囊成功过评。作为一款经久不衰的老药，奥美拉唑可用于胃、十二指肠溃疡、反流性食管炎、卓-艾氏综合征等治疗。直至今日，其在药效、价格、市场认知度等方面依然极具竞争优势。集采冲击下，抑酸药医院市场大洗牌零售渠道“波澜不惊”据中康开思数据显示，2023年全国等级医院抑酸类药物市场规模超210亿元，其中TOP10品种占比超77.6%。抑酸类药全国等级医院销售TOP10来源：中康开思系统、新康界整理其中，奥美拉唑的排名受集采冲击较大，排名已降至第7位。据中康开思数据显示，自2020年国采后，奥美拉唑等级医院销售规模从2019年（集采前）的超53亿元，缩水至2023年的10.8亿元。而第三代质子泵抑制剂雷贝拉唑由于近年来竞争加剧，其等级医院销售规模也呈下滑趋势。由于雷贝拉唑钠肠溶片被纳入第九批集采，今年3月全国开始落地执行，其规模还将进一步受到考验。至于，艾司奥美拉唑的情况也差不多，艾司奥美拉唑镁肠溶片进入第四批集采，艾司奥美拉唑镁肠溶干混悬剂进入了第九批集采。相对而言，作为我国首个自主研发的质子泵抑制剂，丽珠集团的原研药艾普拉唑在2023年开始出现复苏的趋势。据中康开思数据显示，其2023年等级医院销售超28亿元，排名第2。但由于其艾普拉唑肠溶片剂的专利已经到期，后续大概率会有其他本土药企开始布局仿制。此外，还有雷尼替丁、法莫替丁、伏诺拉生等在院内表现较好。其中，雷尼替丁、法莫替丁是以多家国产仿制注射剂品种销售为主；伏诺拉生则是在2020年12月才进入医保，目前还处于专利期（2026年8月到期）。而与等级医院市场的大洗牌相比，全国零售渠道抑酸类药市场显得“波澜不惊”。据中康开思数据显示，2023年全国零售渠道抑酸类药物市场规模超70亿元，其中TOP10品种占比超83.4%。多年来，这些药品排名变化不大，仍以口服制剂的老药为主。其中，奥美拉唑销售规模有小幅下滑，但依旧遥遥领先第2名铝碳酸镁。抑酸类药全国零售渠道销售TOP10来源：中康开思系统、新康界整理综合来看，像奥美拉唑、艾司奥美拉唑、雷贝拉唑、泮托拉唑等品种，属于“两栖全能选手”在等级医院、零售渠道市场都杀入了10名。我国有7100万消化性溃疡患者胃病发生率高达85%，市场潜力巨大近年来，随着生活和工作压力的增加以及饮食习惯的改变，我国消化性溃疡患者数量不断增加。据统计，目前我国胃病发生率高达85%，且患者群体呈年轻化态势。在2021年国内有接近7100万消化性溃疡患者。造成这些疾病的主要原因包括：胃黏膜的减弱保护、过多的胃酸分泌以及幽门螺杆菌感染，并且还受到环境、遗传和药物等因素的影响。其中，特别需要注意幽门螺杆菌感染，其可导致慢性消化不良、胃炎，更是引发胃癌的重要原因。据《中国幽门螺杆菌感染防控》白皮书显示，我国是Hp感染高发地区，感染率高达46.7%，此外家庭Hp感染率高达71.2%，存在明显的家庭聚集性。随着耐药率的不断增加以及现有治疗方案根除率正在下降，目前临床上仍有20%以上的患者根除失败。另据相关研究数据显示，以伏诺拉生为基础的铋剂四联方案治疗中国幽门螺杆菌感染患者根除率高达94.1%，比传统四联疗法提高了20%以上，且安全性良好。而伏诺拉生有可能受益于此，其在2023年11月在国内获批了新适应症，用于与适当的抗生素联用以根除幽门螺杆菌，后续的市场放量值得期待。封面图来源：123rf版权声明/免责声明本文为授权转载文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn点击这里，观看精彩直播！

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- The proton pump inhibitors (PPIs) market size is expected to grow by USD 807.89 million from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 4.86% during the forecast period, according to Technavio Research. The market is categorized by Product (OTC PPIs and Prescription PPIs), Route Of Administration (Oral and Injectable), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America will contribute 36% to the growth of the global market during the forecast period. Factors such as the presence of large pharmaceutical companies that offer both branded and generic PPIs and the presence of a proper regulatory framework for the approval of new drugs in the region drive regional market growth. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a FREE PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global Proton Pump Inhibitors (PPIs) Market 2024-2028 Company Profile: Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., Zydus Lifesciences Ltd. Amgen Inc. - The company offers proton pump inhibitors such as LUMAKRAS with gastric acid-reducing agents and decreased sotorasib concentrations. To gain access to more vendor profiles available with Technavio, buy the report! Proton Pump Inhibitors (PPIs) Market: Health Analysis Proton Pump Inhibitors (PPIs) play a significant role in managing various gastrointestinal conditions, including Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, and Gastritis, effectively suppressing acid production. Helicobacter pylori, a common bacterium, often contributes to Peptic Ulcer Disease, for which both prescription and non-prescription PPIs are used as part of the treatment regimen, ensuring comprehensive therapy against this bacterial infection. The Proton Pump Inhibitor Market showcases a diverse range of medications, including FDA-approved and generic PPIs, aiming to alleviate symptoms associated with acid-related disorders like Heartburn, Erosive Esophagitis, and NSAID-Induced Ulcers. Understanding the potential side effects of Proton Pump Inhibitors is crucial, as they are associated with complications such as Duodenal Ulcers, necessitating careful consideration of their usage and monitoring for optimal gastrointestinal health. Heartburn, often associated with Acid-related Disorders, manifests as a burning sensation in the chest due to stomach acid reflux into the esophagus. This common symptom occurs post-meals, triggered by specific foods or lying down, contributing significantly to Acid-related Disorders' discomfort. Managing heartburn involves dietary modifications, maintaining an upright posture after eating, and utilizing medications to mitigate stomach acid production. Chronic heartburn, if left unaddressed, may lead to erosive esophagitis or Barrett's esophagus, highlighting its role within Acid-related Disorders and emphasizing the need for prompt intervention to alleviate symptoms and prevent complications. Proton Pump Inhibitors (PPIs) Market: Segmentation Analysis The OTC PPIs segment will be significant during the forecast period. The products in this segment are defined as medicines that are sold directly to patients or consumers without a prescription from a healthcare professional. Furthermore, the availability of OTC PPIs provides patients with an option for self-medication and reduces the financial burden associated with medication treatment. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report These six medications—Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, and Dexlansoprazole—belong to the class of proton pump inhibitors, commonly prescribed to treat various gastrointestinal conditions by reducing stomach acid production. Each drug within this group exhibits distinct pharmacokinetic properties and efficacy profiles, catering to individual patient needs for managing acid-related disorders. "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio Proton Pump Inhibitors (PPIs) Market: Driver & Trend: Driver Reformulation of drugs Growth in prescription rate Strong prevalence of gastroesophageal reflux disease Reformulation of drugs drives market growth. It provides an opportunity to grab patent term extensions, which can delay the entry of generic versions into the market. The availability of two dosage forms, NEXIUM 10 mg and 20 mg, will increase the consumption of the drug for various indications, particularly acid-related diseases, in both children aged one year and above the older patients with difficulty in swallowing. The rising prevalence of obesity is a leading market trend. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information. Unraveling Therapeutic Efficacy and Potential Complications in Gastrointestinal Health The Proton Pump Inhibitors (PPIs) Market comprises an extensive range of medications tailored to manage diverse acid-related disorders like Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, and Gastritis. FDA-approved prescription PPIs play a significant role in treating conditions such as Zollinger-Ellison Syndrome and NSAID-Induced Ulcers, contributing significantly to gastrointestinal health and acid suppression. It's essential to recognize that both non-prescription and generic PPIs exist within this market, each exhibiting distinct efficacy profiles and potential side effects, including complications associated with prolonged use such as erosive esophagitis. Understanding the complexities of these medications is crucial for addressing various conditions and ensuring patient well-being amid the dynamic landscape of Proton Pump Inhibitors (PPIs) Market. Related Reports: The tyrosine kinase inhibitors market is estimated to grow at a CAGR of 8.93% between 2022 and 2027. The market size is forecasted to increase by USD 24.12 billion. The global PARP (poly ADP-ribose polymerase) inhibitors market size is estimated to grow by USD 5,555.99 million at a CAGR of 13.25% between 2023 and 2028. What are the key data covered in this proton pump inhibitors (PPIs) market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the proton pump inhibitors (PPIs) market between 2023 and 2028. Precise estimation of the proton pump inhibitors (PPIs) market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the proton pump inhibitors (PPIs) market across North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of proton pump inhibitors (PPIs) market vendors. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Product Market Segmentation by Route of Administration Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

☝ 点击上方 一键预约 ☝   最新最热的医药健康新闻政策近日，国家药品监督管理局官网的消息称，重庆药友制药的质子泵抑制剂雷贝拉唑钠肠溶片获批上市。事实上，雷贝拉唑钠肠溶片正是第九批集采的品种，而在数次集采的冲击下，这个百亿抑酸药市场开始重新洗牌。图片来源：NMPA01国内有7100万消化性溃疡患者市场规模达到了289.7亿质子泵抑制剂（PPI）是一种重要的抑制胃酸分泌药物，已成为临床治疗的重要选择。PPI在治疗多种胃酸相关性疾病方面表现出卓越疗效，如溃疡、胃食管反流病、十二指肠溃疡和卓艾综合征等。PPI通过抑制H+/K+-ATP酶减少胃酸分泌，具有高特异性、强效、迅速和持久的抑酸作用，它可以使溃疡愈合率达到90%以上，因此成为市面上最强大、广泛应用的抑制胃酸分泌药物之一。消化性溃疡是慢性溃疡，常见于胃和十二指肠。它的主要原因包括胃黏膜的减弱保护、过多的胃酸分泌以及幽门螺杆菌感染，还受到环境、遗传和药物等因素的影响。近年来，随着生活和工作压力的增加以及饮食习惯的改变，国内消化性溃疡患者数量不断增加。据统计，2021年，国内已有接近7100万的消化性溃疡患者，患病率接近8%。患者人数多且大多属于慢病，国内PPI药物的市场需求持续上升。相关数据显示，2022年，国内PPI的市场规模达到了289.7亿元。2016-2022年国内质子泵抑制剂市场销售情况来源：公开资料，中康产业研究院整理由于PPI药物用量大，它们一直是药品集中采购的重点关注对象。自从2020年第三批药品集采开始，逐渐涵盖了多种PPI药物。在医保费用控制和集中采购政策的影响下，PPI市场销售额在2020年首次出现负增长。到2022年，PPI市场规模重新呈现增长趋势。目前，国内市场上常见的PPI药物主要有：奥美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑、艾司奥美拉唑、艾普拉唑。中康开思系统的数据显示，2023年上半年，等级医院+零售市场的销售额超过10亿元的PPI药物有4个，分别是奥美拉唑、雷贝拉唑、艾司奥美拉唑和艾普拉唑。2023年上半年，等级医院销售额第一的是艾普拉唑，销售额达17.26亿元，增长率26.12%；零售市场销售额第一的PPI药物是奥美拉唑，销售额为10.22亿元。部分国内已上市质子泵抑制剂2023年H1销售情况    来源于中康开思系统，中康产业研究院整理02创新药开始脱颖而出受到集采的影响，加上多个质子泵抑制剂被纳入重点监控目录，PPI药物近几年的市场规模有所下滑，但同时，也为创新药发展迎来宝贵机遇。2023年上半年等级医院销售额第一的艾普拉唑，是我国首个自主研发的质子泵抑制剂，原研厂家是丽珠集团，专利从海外许可引进。艾普拉唑于2007年获得批准上市，并已纳入医保。2023年6月，由轩竹生物自主研发，我国拥有自主知识产权的PPI创新药安奈拉唑获批上市。它采用独特的结构优化设计，代谢方式更多样，实现肠肾双通道均衡排泄，减轻对肾脏的负担。在激烈竞争的质子泵抑制剂市场，安奈拉唑作为独家创新药品种，还拥有专利保护，具备显著优势，有望成为疗效稳定、合并用药风险小、安全性良好的新一代PPI药物。尽管质子泵抑制剂在抑酸药领域占有主导地位，但另一种创新抑酸药钾离子竞争性酸阻滞剂（P-CAB）的出现为市场带来新的机遇和挑战。不同于PPI药物，P-CAB可以直接与H+/K+-ATP酶上的结合位点竞争，以争夺钾离子，同时有效地抑制H+/K+-ATP酶的活性，既在其静息状态又在激活状态下，从而成功降低胃酸分泌。与PPI药物相比，P-CAB药物具有更迅速的起效、在首次剂量即达到全效、更强效地抑制胃酸，以及较长的半衰期。   2019年底，新一代抑酸剂P-CAB药物伏诺拉生片在中国获批上市，原研厂家是日本武田制药。伏诺拉生片在2020年末被纳入医保目录，此后市场规模增势迅猛。根据中康开思系统，2022年伏诺拉生片在等级医院的销售额达到了5.46亿元，增速达139.6%。目前伏诺拉生片已有多家仿制药获批上市，还有超过5家企业的仿制药申报正在受理中，包括正大天晴、康恩贝、石四药等。2022年4月，国产首款P-CAB药物替戈拉生获批上市。随着越来越多的P-CAB创新药和仿制药的问世，PPI药物的市场格局将进一步改变。国内已上市钾离子竞争性酸阻滞剂来源于公开资料，中康产业研究院整理03结语质子泵抑制剂作为抑制胃酸分泌的关键药物，在临床治疗中发挥着不可替代的作用。近年来，新一代PPI和P-CAB药物的出现提供了更多选择，改善了治疗效果，为市场带来了新的机遇，同时也为创新药的发展提供了良机。随着这些新药物的涌现，质子泵抑制剂市场将面临更大的竞争和挑战，但也为患者带来了更多治疗选择，推动抑酸药领域的进步。（来源:新康界 作者:Serien）药闻康策新媒体矩阵微信公众号点击下方  一键关注  【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、收藏、点赞、点在看